Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Younes, Anas; Sehn, Laurie; Johnson, Peter; Zinzani, Pier; Hong, Xiaonan; Zhu, Jun; Patti, Caterina; Belada, David; Samoilova, Olga; Suh, Cheolwon; Leppae, Sirpa; Rai, Shinya; Turgut, Mehmet; Jurczak, Wojciech; Cheung, Matthew; Gurion, Ronit; Yeh, Su-Peng; Lopez-Hernandez, Andres; Duehrsen, Ulrich; Thieblemont, Catherine; Chiattone, Carlos; Balasubramanian, Sriram; Carey, Jodi; Liu, Grace; Shreeve, S.; Sun, Steven; Zhuang, Sen; Vermeulen, Jessica; Staudt, Louis; Wilson, Wyndham; Fisher, Richard; Engert, Andreas; Stadtmauer, Edward; Wei, Lee-Jen

doi:10.1200/jco.18.02403

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Atıf İçin Kopyala

Younes A., Sehn L. H., Johnson P., Zinzani P. L., Hong X., Zhu J., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.37, sa.15, ss.1285-1306, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 37 Sayı: 15
Basım Tarihi: 2019
Doi Numarası: 10.1200/jco.18.02403
Dergi Adı: JOURNAL OF CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1285-1306
Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

PURPOSE Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated non-germinal center B-cell DLBCL.